Cortagen (Ala-Glu-Asp-Pro): Injured Nerve Function and a Tissue-Specificity Puzzle

Cortagen is a cortex-derived tetrapeptide with published work on injured nerve function and cerebral ischaemia — plus a microarray study of its effect on gene expression in heart, which complicates the tissue-specificity story.

cortagen bioregulator khavinson Ala-Glu-Asp-Pro AEDP neuroprotection nerve regeneration

Key Research Findings

  • Cortagen is the tetrapeptide Ala-Glu-Asp-Pro (AEDP), C17H26N4O9, 430.41 g/mol, classified as brain-cortex derived.
  • Three papers name it; the most recent is from 2011.
  • A delayed effect on injured nerve function was reported (PMID 12134478) — the effect emerged over time, not acutely.
  • A microarray study measured its effect on gene expression in mouse HEART (PMID 15159690), which complicates the family tissue-specificity claim.
  • Two of three studies are combination or cross-tissue designs, limiting attribution.
  • No amount is established for any species.

What Cortagen Is

Cortagen is a synthetic tetrapeptide, Ala-Glu-Asp-Pro (AEDP), C17H26N4O9, 430.41 g/mol. Within the bioregulator family it is classified as brain-cortex derived, and it is one of the members with published work naming it.

What makes Cortagen worth reading closely is not the size of its literature but a tension inside it — one that bears directly on the family's central claim about tissue specificity.

Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.

What the Published Studies Report

Injured nerve function

A study in Doklady Biological Sciences reported a delayed effect of Cortagen on restoration of injured nerve function (Kolosova et al., 2002, PMID 12134478). The word "delayed" in the title is doing real work: the reported effect emerged over time rather than acutely, which shapes how any follow-up would need to be designed.

Chronic cerebral ischaemia

Work in Eksperimental'naia i Klinicheskaia Farmakologiia examined Cortexin and Cortagen as correcting agents in functional and metabolic disorders of the brain in chronic ischaemia (Zarubina & Shabanov, 2011, PMID 21476278). As with several papers in this family, the design pairs the tetrapeptide with a separate preparation, so effects cannot be assigned to Cortagen alone.

Gene expression — in heart

The most interesting entry is a microarray study elucidating the effect of the brain-cortex tetrapeptide Cortagen on gene expression in mouse heart (Anisimov et al., Neuro Endocrinol Lett 2004, PMID 15159690).

That is worth pausing on. A compound classified as cortex-associated was measured for transcriptional effects in cardiac tissue. Whatever the result, the choice of design implies the investigators did not treat tissue association as a constraint — which sits awkwardly beside the family's framing of each peptide as organ-specific. Anyone using the tissue-specificity claim as a premise should read this paper before relying on it.

Reading the Evidence

The literature is small and old. Three papers, the most recent from 2011, largely in Russian-language journals.

Two of three are combination or cross-tissue designs. That limits attribution more than the abstract count of papers suggests.

No amount is established for any species or context, because no controlled human programme exists.

Structure and Handling

  • Sequence. Ala-Glu-Asp-Pro (AEDP), tetrapeptide.
  • Formula. C17H26N4O9, 430.41 g/mol.
  • Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
  • Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
  • Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.

Pinealon (Glu-Asp-Arg) is the other CNS-associated member and has a somewhat larger literature. Vilon appears in the same early microarray line of work. See the bioregulator overview for the full family.

Frequently Asked Questions

What is Cortagen?

Cortagen is a synthetic tetrapeptide, Ala-Glu-Asp-Pro (AEDP), C17H26N4O9, 430.41 g/mol, classified within the Khavinson bioregulator family as brain-cortex derived.

What does the research on Cortagen show?

Three papers name it: a delayed effect on restoration of injured nerve function (PMID 12134478), work on chronic cerebral ischaemia paired with a separate preparation (PMID 21476278), and a microarray study of its effect on gene expression in mouse heart (PMID 15159690).

Why does a cortex peptide have a study in heart tissue?

That is the interesting tension in this literature. A compound classified as cortex-associated was measured for transcriptional effects in cardiac tissue, which suggests the investigators did not treat tissue association as a constraint. Anyone relying on the family tissue-specificity claim as a premise should read that paper first.

Is there an established Cortagen dosage?

No. No controlled human programme exists, so no published figure is available for any population or context.

How large is the Cortagen literature?

Small: three papers naming it, the most recent from 2011, largely in Russian-language journals. Two of the three are combination or cross-tissue designs, which limits what can be attributed to the tetrapeptide alone.

References

  1. Kolosova LI, Malinin VV, Vladimirova IG, Grigor'ev GP. The delayed effect of cortagen on the restoration of injured nerve function Doklady Biological Sciences (2002)
  2. Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray Neuro Endocrinology Letters (2004)
  3. Zarubina IV, Shabanov PD. Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia Eksperimental'naia i Klinicheskaia Farmakologiia (2011)
Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.